A PHD in immunosuppression: oxygen-sensing pathways regulate immunosuppressive Tregs

Weiping Zou, Yatrik M. Shah


Commentary

The oxygen-sensing prolyl hydroxylase domain (PHD) enzymes are key to maintaining tissue homeostasis during hypoxia via their regulation of the expression and activity of HIF, the master transcription factor for the hypoxic response. In this issue of the *JCI*, Yamamoto, Hester, and colleagues show that temporal and reversible inhibition of PHD2 in vivo leads to systemic autoimmune disorder. The work demonstrates that a reduction of PHD2 leads to impairment of immunosuppressive Treg function via a HIF2α-dependent mechanism, without altering Foxp3 expression. This study indicates that a PHD2/HIF2α axis is critical for maintaining proper Treg function.

Find the latest version:

http://jci.me/130009/pdf
A PHD in immunosuppression: oxygen-sensing pathways regulate immunosuppressive Tregs

Weiping Zou1,2,3,4 and Yatrik M. Shah4,5,6

1Department of Surgery, 2Department of Pathology, 3Center of Excellence for Cancer Immunology and Immunotherapy, 4Rogel Cancer Center, 5Department of Molecular and Integrative Physiology, and 6Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

The oxygen-sensing prolyl hydroxylase domain (PHD) enzymes are key to maintaining tissue homeostasis during hypoxia via their regulation of the expression and activity of HIF, the master transcription factor for the hypoxic response. In this issue of the JCI, Yamamoto, Hester, and colleagues show that temporal and reversible inhibition of PHD2 in vivo leads to systemic autoimmune disorder. The work demonstrates that a reduction of PHD2 leads to impairment of immunosuppressive Treg function via a HIF2α-dependent mechanism, without altering Foxp3 expression. This study indicates that a PHD2/HIF2α axis is critical for maintaining proper Treg function.

Oxygen-sensing pathways

The cellular response to hypoxia is regulated by the heterodimeric transcription factor HIF. HIF consists of a constitutively expressed HIF1β subunit, which is encoded by the aryl hydrocarbon receptor nuclear translocator (ARNT) gene, and an oxygen-sensitive HIFα subunit. The two best-characterized α subunits are HIF1α and HIF2α (1). HIF is regulated by oxygen via the action of prolyl hydroxylase domain (PHD) enzymes, which are iron-and α-ketoglutarate–dependent dioxygenases that utilize molecular O2 for hydroxylation reactions. Under adequate cellular oxygen, iron, and α-ketoglutarate levels, PHDs hydroxylate HIFα on conserved proline residues. Hydroxylation leads to the binding of von Hippel–Lindau (VHL) protein and recruitment of an E3 ubiquitin ligase complex, resulting in rapid degradation of HIF (2). During hypoxia, HIFα is stabilized, binds to ARNT, and regulates target genes that control angiogenesis, cellular metabolism, iron handling, survival, proliferation, and migration. The three PHD isoforms PHD1, PHD2, and PHD3 (also termed EGLN2, EGLN1, and EGLN3, respectively) have overlapping but unique tissue expression patterns. PHD2 is ubiquitously expressed, and whole-body disruption of PHD2 leads to early embryonic lethality. PHD1 and PHD3 are more selectively expressed, and mice with whole-body knockout of PHD1 or PHD3 are viable (3). The role of HIF signaling in the immune system has been a subject of intense research and debate, but the mechanisms have remained unclear.

Oxygen-sensing pathways in immune cells

Tissue hypoxia and HIF activation occur following tissue injury, infection, inflammation, and rapid tumor growth. Resident or recruited immune cells must rapidly activate HIF to adapt and function in a hypoxic environment. In tissues that demonstrate a basal hypoxic response (e.g., the intestine), physiological HIF expression is essential to maintain immune tolerance and function, which are critical for tissue homeostasis (4). During a robust injury or in the setting of chronic inflammation, including cancer, pathological hypoxia via constitutive HIF expression leads to the activation of proinflammatory mediators and tissue damage. The role of hypoxia and HIF activation in immune cells is complex and may be cell-type dependent. It is clear that hypoxia and HIF signaling affect metabolic pathways, in particular by inducing glycolytic gene expression, but the functional responses differ in different cell types. Therefore, many studies have utilized Cre-mediated deletion to understand the role of HIFs in individual immune cell populations, which have demonstrated the cell-autonomous dependency of HIFs in modulating immune cell function. However, those studies lacked temporal regulation, and because of lineage- and developmental stage–specific activation of various Cre recombinases, the results have at times been discordant (5–12). Furthermore, the approach of targeting HIF function in specific cell types does not address the role of heterocellular crosstalk in the response to hypoxia in the inflammatory or injured foci or in cancer.

In this issue, Yamamoto, Hester, and colleagues developed an inducible mouse model to assess the hypoxia/HIF pathway using an RNA interference knockdown approach in vivo (13). Specifically, they cloned reverse tetracycline transactivator (ROSA26) driven by the endogenous ROSA26 promoter and a single-copy tetracycline response element (TRE) controlling a GFP-shRNA cassette expressing an shRNA sequence for PHD2, HIF1α, or HIF2α downstream of the collagen type I (Col1a1) gene. Upon doxycycline treatment, the mice expressed the shRNAs and GFP, enabling temporal and reversible gene silencing and cellular tracking in adult mice (Figure 1). The authors found that mice with knockdown of Phd2 became grossly sick, characterized by weight loss, alopecia, and anemia. The anemia was surprising, as HIF activation is known to increase erythropoi-
The phenotype of the shPhd2 mice was consistent with that of a progressive autoimmune disorder. To determine whether what they observed was immune cell autonomous, the authors generated bone marrow chimeras and showed that transfer of hemopoietic cells from shPhd2 mice was sufficient to induce the immune phenotype in the recipients. Examination of T cell subsets in shPhd2 mice revealed an increase in the absolute numbers of these cells, including a surprising increase in the number of Tregs, which maintain homeostasis and self-tolerance. Despite this finding, shPhd2 mice resembled other models with gross pathologies associated with disruption of Tregs.

PHD2, Tregs, and autoimmunity

The phenotype of the shPhd2 mice was consistent with that of a progressive autoimmune disorder. To determine whether what they observed was immune cell autonomous, the authors generated bone marrow chimeras and showed that transfer of hemopoietic cells from shPhd2 mice was sufficient to induce the immune phenotype in the recipients. Examination of T cell subsets in shPhd2 mice revealed an increase in the absolute numbers of these cells, including a surprising increase in the number of Tregs, which maintain homeostasis and self-tolerance. Despite this finding, shPhd2 mice resembled other models with gross pathologies associated with disruption of Tregs.
Further study by Yamamoto, Hester, and coworkers using a model of skin allograft rejection demonstrated that Tregs isolated from shPhd2 mice were unable to suppress T effector function, leading to allograft rejection and impaired survival (Figure 1). They complemented this work with in vitro assays that demonstrated a complete loss of Treg function, despite maintenance of Foxp3 expression. These data are in contrast to a study showing the effect of Vhl inactivation using a Foxp3-driven Cre, which resulted in reduced Foxp3 expression and an inflammatory phenotype, dependent on HIF1α (18). This discrepancy may be related to differences between temporal knockdown compared with constitutive disruption via Cre-mediated deletion and to differences in PHD2/HIF2α signaling compared with the HIF1α-mediated processes implicated in the Vhl inactivation model. Although the authors suggest a cell-autonomous role for PHD2 in Foxp3+ cells, future work crossing their line with a Foxp3-dependent system is needed to better understand the direct role of PHD2 in Tregs. In addition, given the autoimmune phenotype in shPhd2 mice and the reported role of HIF in Th17 cells (6, 9, 19), future studies should examine the Th17 cell compartment in shPhd2 mice.

Inhibition of mitochondrial complex III leads to increased hypoxic metabolite 2-hydroxylglutarate (2-HG), which has also been shown to suppress Treg function. In that setting, expression of Foxp3 expression is not altered, but several immunoregulatory genes are inhibited (20). Although Yamamoto, Hester, and colleagues did not identify the mechanism by which downregulation of PHD2 suppresses Treg function, the changes in cytokine expression were consistent with those observed upon mitochondrial complex III inhibition. Immune responses require aerobic glycolysis to promote T cell proliferation and effector function, and immunometabolism and immune cell function are integrated via HIF signaling (21). Therefore, it would be interesting to determine whether the phenotype of the Tregs from shPhd2 mice is dependent on cellular metabolic pathway alteration.

**Therapeutic implications**

Currently, many orally active PHD inhibitors are in clinical trials involving patients with chronic kidney disease (CKD), for whom the inhibitors are intended to stimulate erythropoiesis to improve anemia. PHD inhibitors have so far been shown to be safe and effective in preclinical models and in patients (22). Recently, a battery of publications has shown that PHD inhibitors are beneficial in models of intestinal inflammation (23), and there is interest in assessing their action in patients with inflammatory bowel disease, which may require higher doses than those used to treat CKD. The work of Yamamoto, Hester, and coworkers argues for some caution and suggests that it will be important to monitor Treg function in patients treated with PHD inhibitors. Furthermore, since PHD inhibitors may affect Tregs, it would be interesting to test the antitumor potential of these drugs in syngenic models of cancer. In summary, the work highlights the need for further studies of the role of PHD2 and HIF2α inhibitors in autoimmune disorders, inflammation, and cancer.

**Acknowledgments**

This work was supported by NIH grants CA148828 and DK095201 (to YMS) and CA217648, CA123088, CA099985, CA193136, and CA152470 (to WZ) and by the NIH through the University of Michigan Rogel Cancer Center grant CA46592 (to YMS and WZ).

Address correspondence to: Yatrik M. Shah, University of Michigan, Medical Science Building II, Ann Arbor, Michigan, 48108, USA. Phone: 734.615.0567. Email: shahy@umich.edu. Or to: Weiping Zou, University of Michigan, Biomedical Science Research Building, Ann Arbor Michigan, USA. Phone: 734.615.5554, Email: wzou@umich.edu.